DOI QR코드

DOI QR Code

p53 Exon 4 (codon 72) Polymorphism and Exon 7 (codon 249) Mutation in Breast Cancer Patients in Southern Region(Madurai) of Tamil Nadu

  • Vijayaraman, Kiruthiga Perumal (Department of Biotechnology, Alagappa University) ;
  • Veluchamy, Mohanasundari (Department of Biotechnology, Alagappa University) ;
  • Murugesan, Pravina (Department of Biotechnology, Alagappa University) ;
  • Shanmugiah, Karutha Pandian (Department of Biotechnology, Alagappa University) ;
  • Kasi, Pandima Devi (Department of Biotechnology, Alagappa University)
  • Published : 2012.02.29

Abstract

Background: We investigated the association between polymorphisms in the $p53$ tumor suppressor gene and breast cancer risk in women especially in the Southern part of India. Methods: Genotyping was performed for 50 breast cancer women and 50 controls to determine the status of $p53$ exon 4 codon 72 polymorphism and exon 7 codon 249 mutation and their possible role in breast cancer risk. Results: Frequency of Arg/Arg at codon 72 was 18% in controls and 28% in patients, Arg/Pro frequency was 56% and 66%, Pro/Pro genotype was 8% in controls and 8% in patients. No significance was observed for breast cancer risk with either Arg/Arg or Pro/Pro genotype in codon 72 polymorphism. Similarly, mutation analysis of exon 7 codon 249 revealed that 72% of breast cancer patients have mutation, which is not statistically significant. However, there is a strong association between increase in exon 7 codon 249 mutation and exposure to pollution. Conclusion: The results suggested that there is no risk for exon 4 with Arg/Arg or Pro/Pro polymorphisms in the $p53$ gene and there is no strong correlation between breast cancer patients and mutation in exon 7 codon 249 in South Indian women.

Keywords

Breast cancer;p53;exon 4 codon 72;exon 7 codon 249;South India

References

  1. Abdaheer S, Khan E (2009). Shape based classification of breast tumors using fractal analysis. IEEE, 272-5.
  2. Alawadi S, Ghabreau L, Alsaleh M, et al (2010). P53 gene polymorphisms and breast cancer risk in Arab women. Med Oncol, 28, 709-15.
  3. Andersen TI, Holm R, Nesland JM, et al (1993). Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer, 68, 540-8. https://doi.org/10.1038/bjc.1993.383
  4. Beckman G, Birgander R, Sjalander A, et al (1994). Is p53 polymorphism maintained by natural selection? Hum Hered, 44, 266-70. https://doi.org/10.1159/000154228
  5. Buyru N, Tigli H, Dalay N (2003). P53 codon 72 polymorphism in breast cancer. Oncol Rep, 10, 711-4.
  6. Chen FM, Hou MF, Wang JY, et al (2004). High frequency of G/C transversion on p53 gene alterations in breast cancers from Taiwan. Cancer Lett, 207, 59-67. https://doi.org/10.1016/j.canlet.2003.12.005
  7. Chopra R (2001). The Indian scene. J Clin Oncol, 19, 106s-11s.
  8. Chosdol K, Ahuja A, Rathore A, et al (2002). Study of p53 codon 72 polymorphism in various etnic groups of North India. Curr Sci, 82, 1253-5.
  9. Coursaget P, Depril N, Chabaud M, et al (1993). High prevalence of mutations at codon 249 of the p53 gene in hepatocellular carcinomas from Senegal. Br J Cancer, 67, 1395-7. https://doi.org/10.1038/bjc.1993.258
  10. Damin APS, Frazzon APG, Damin DC, et al (2006). Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev, 30, 523-9. https://doi.org/10.1016/j.cdp.2006.09.007
  11. Ganjewala D (2009). Prevalence of cancers in some parts of Madhya Pradesh and Uttar Pradesh in India. Acad J Cancer Res, 2, 12-8.
  12. Gohrke WS, Rebbeck TR, Besenfelder W, et al (1998). p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res, 18, 2095-9.
  13. Hsu IC, Metcalf RA, Sun T, et al (1991). Mutational hot spot in the p53 gene in human hepatocellular carcinomas. Nature, 350, 427-8. https://doi.org/10.1038/350427a0
  14. Hussain SP, Amstad P, Raja K, et al (2001). Mutability of p53 hotspot codons to benzo (a) pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung. Cancer Res, 61, 6350-5.
  15. Igetei R, Otegbayo JA, Ndububa DA, et al (2008). Detection of p53 codon 249 mutation in Nigerian patients with hepatocellular carcinoma using a novel evaluation of cellfree DNA. Ann Hepatol, 7, 339-44.
  16. Jeffreys AJ, Morton DB (1987). DNA fingerprints of dogs and cats. Anim Genet, 18, 1-15.
  17. Kalemi TG, Lambropoulos AF, Gueorguiev M, et al (2005). The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Letters, 222, 57-65. https://doi.org/10.1016/j.canlet.2004.11.025
  18. Katiyar S, Dash BC, Thakur V, et al (2000). P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India. Cancer, 88, 1565-73. https://doi.org/10.1002/(SICI)1097-0142(20000401)88:7<1565::AID-CNCR10>3.0.CO;2-9
  19. Keshava C, Frye BL, Wolff MS, et al (2002). Waf-1 (p21) and p53 polymorphisms in breast cancer. Cancer Epidemiol Biomarkers Prev, 11, 127-30.
  20. Liu H, Wang Y, Zhou Q, et al (2002). The point mutation of p53 gene exon7 in hepatocellular carcinoma from Anhui Province, a non HCC prevalent area in China. World J Gastroenterol, 8, 480-2. https://doi.org/10.3748/wjg.v8.i3.480
  21. Mabrouk I, Baccouche S, El Abed RYM, et al (2003). No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann NY Acad Sci, 1010, 764-70. https://doi.org/10.1196/annals.1299.137
  22. Makwane N, Saxena A (2009). Study of mutations in p53 tumour suppressor gene in human sporadic breast cancers. IJCB, 24, 223-8.
  23. Mirmomeni MH, Arveisi S, Ghobadi S, et al (2009). An investigation of point mutations at 7th exon of gene P53 in Hepatocellular Carcinoma patients in Kermanshah Province and the study of mutation in liver specimens of mice exposed to aflatoxin B1. Res J Biol Sci, 4, 107-12.
  24. Nogueira JA, Ono-Nita SK, Nita ME, et al (2009). 249 TP 53 mutation has high prevalence and is correlated with larger and poorly differentiated HCC in Brazilian patients. BMC Cancer, 9, 204. https://doi.org/10.1186/1471-2407-9-204
  25. Noma C, Miyoshi Y, Taguchi T, et al (2004). Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Letters, 210, 197-03. https://doi.org/10.1016/j.canlet.2004.03.031
  26. Ohayon, T, Baruch GR, Papa MZ, et al (2005). The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer, 92, 1144-8. https://doi.org/10.1038/sj.bjc.6602451
  27. Papadakis EN, Dokianakis DN, Spandidos DA (2000). p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun, 3, 389-2. https://doi.org/10.1006/mcbr.2000.0241
  28. Peng XM, Peng WW, Yao JL (1998). Codon 249 mutations of p53 gene in development of hepatocellular carcinoma. World J Gastroenterol, 4, 125-7.
  29. Pugalendhi P, Manoharan S, Baskaran N, et al (2010). Effects of genistein and daidzein, in combination, on the expression pattern of biomolecular markers (p53, PCNA, VEGF, iNOS, Bcl-2, and Bax) during 7, 12-dimethylbenz (a) anthracene (DMBA) induced mammary carcinogenesis in Sprague- Dawley rats. Int J Biol Med Res, 1, 264-71.
  30. Pushkala K, Gupta PD (2009). Prevalence of breast cancer in menopausal blind women. Int J Med Sci, 1, 425-31.
  31. Singh V, Rastogi N, Mathur N, et al (2008). Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol, 18, 48-57. https://doi.org/10.1016/j.annepidem.2007.06.006
  32. Sjalander A, Birgander R, Hallmans G, et al (1996). p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis, 17, 1313-16. https://doi.org/10.1093/carcin/17.6.1313
  33. Suspitsin EN, Buslov KG, Grigoriev MY, et al (2003). Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer, 103, 431-3. https://doi.org/10.1002/ijc.10834
  34. Takiar R, Nadayil D, Nandakumar A (2010). Projections of number of cancer cases in India (2010-2020) by cancer groups. Asian Pac J Cancer Prev, 11, 1045-9.
  35. Thorlacius S, Börresen AL, Eyfjörd JE (1993). Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res, 53, 1637-41.
  36. Weir R, Day P, Ali W (2007). Risk factors for breast cancer in women. A systematic review of the literature. NZHTA Report, 10.

Cited by

  1. TP53 Polymorphisms in Sporadic North Indian Breast Cancer Patients vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6871
  2. Lack of Association of Intron 3 16 bp Polymorphism of TP53 with Breast Cancer among Iranian-Azeri Patients vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2631
  3. Association of TP53 PIN3 polymorphism with breast cancer in Moroccan population vol.35, pp.12, 2014, https://doi.org/10.1007/s13277-014-2556-y
  4. No Evidence of Association of the Arg72Pro p53 Gene Polymorphism with Cancer Risk in the Saudi Population: a Meta-Analysis vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5663
  5. P53 Polymorphism at Codon 72 is Associated with Keratocystic Odontogenic Tumors in the Thai Population vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1997
  6. Lack of Influence of TP53 Arg72Pro and 16bp Duplication Polymorphisms on Risk of Breast Cancer in Iran vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2971
  7. Co-expression of ING4 and P53 enhances hypopharyngeal cancer chemosensitivity to cisplatin in vivo vol.14, pp.3, 2016, https://doi.org/10.3892/mmr.2016.5552
  8. The Evaluation of p53 Polymorphism at Codon 72 and Association With Breast Cancer in Iran: A Systematic Review and Meta-analysis vol.21, pp.4, 2016, https://doi.org/10.15430/JCP.2016.21.4.288
  9. Breast cancer risk in relation to TP53 codon 72 and CDH1 gene polymorphisms in the Bangladeshi women vol.37, pp.6, 2016, https://doi.org/10.1007/s13277-015-4612-7
  10. Association of p53 codon 72 polymorphism and survival of North Indian lung cancer patients treated with platinum-based chemotherapy vol.43, pp.12, 2016, https://doi.org/10.1007/s11033-016-4072-1